The biotech recently became a commercial-stage company.Gene editing, in which researchers manipulate patients' genetic code to treat genetic illnesses, has been around for a couple of decades. But it has made incredible progress in the past five years. CRISPR Therapeutics (CRSP -6.82%), a mid-cap biotech, has proven to be one of the more exciting players in this promising area.The company's progress has not delivered strong returns in the past half-decade -- CRISPR Therapeutics has underperformed the market ...